CTI BioPharma Announces Independent DMC Recommendation to Continue GOG-0212 Phase 3 Study of OPAXIO™ as Maintenance Therapy in Ovarian Cancer, an NRG Oncology/GOG Study

Feb 03, 2015, 01:30 ET from CTI BioPharma Corp.

$countyNameToPathMap.put("sp